Proceedings from the first in a series of 11 integrated webinars
held in association with the 2020 ONS Annual Congress. Featuring
perspectives from Dr Virginia Kaklamani, Ms Marissa Marti, Dr Joyce
O’Shaughnessy and Mr Daniel G Pizana.
Introduction (00:00)
Neoadjuvant therapy for patients with localized HER2-positive
breast cancer (2:20)
Activity and tolerability of T-DM1 as adjuvant therapy
(7:24)
Clinical experience with neratinib as postadjuvant therapy for
patients with HER2-positive breast cancer (11:00)
Results of the KATHERINE study comparing T-DM1 to trastuzumab
and the APHINITY trial evaluating pertuzumab, trastuzumab and
chemotherapy as adjuvant therapy for HER2-positive early breast
cancer (15:48)
Benefits and risks with the novel agents trastuzumab deruxtecan
and tucatinib for HER2-positive metastatic breast cancer (mBC)
(26:13)
Role of the immune checkpoint inhibitors atezolizumab and
pembrolizumab and the novel antibody-drug conjugate sacituzumab
govitecan for triple-negative breast cancer (38:49)
Genomic testing for patients with breast cancer; integration of
PARP inhibitors into the therapeutic algorithm for patients with
mBC and germline BRCA mutations (52:59)
Efficacy and tolerability of the CDK4/6 inhibitors palbociclib,
abemaciclib and ribociclib for ER-positive, HER2-negative mBC
(1:07:56)
Activity of alpelisib in patients with ER-positive mBC and
PIK3CA mutations; results of the SOLAR-1 trial evaluating alpelisib
with fulvestrant (1:16:19)
Featuring the video recorded proceedings of events held in conjunction with important scientific symposia, live webcasts and closed meetings featuring the perspectives of renowned clinical investigators, these videos provide an overview of important advances in the management of a number of solid tumors and hematologic cancers.